Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2011 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
1989
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report
2011
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
1995
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data
1994
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Eosinophil function in health and disease
1995
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.
1992
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
1993
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
1992
Biochemotherapy for advanced melanoma
2002
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
1990
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
1988
Role of Biochemical Mediators in Clinical Nutrition and Surgical Metabolism
1988
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
1990 Standout
Renal-Cell Carcinoma
1996 Standout
PLGA-based nanoparticles: An overview of biomedical applications
2012 Standout
Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
2000
Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
1993
Pharmacodynamics in cancer therapy.
1990
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer
2006
Hepatocellular carcinoma
2012 Standout
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
1990
The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia
1992 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Immunology and immunotherapy of colorectal cancer
2003
The Impact of Interleukin-2 on Survival in Renal Cancer: A Multivariate Analysis
1993
Validation of the HCC‐MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy
2008
Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma
1995
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
2017
Metazoan MicroRNAs
2018 Standout
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Malignant Gliomas in Adults
2008 Standout
Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma
1990
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Unexplained Spontaneous Regression and Alpha‐interferon as Treatment for Metastatic Renal Carcinoma
1989
Head and Neck Cancer
1993 Standout
Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors
1994
Novel treatment strategies in clear-cell metastatic renal cell carcinoma
2005
Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
1988 Standout
Suppression of Tumor Growth and Metastasis of Murine Renal Adenocarcinoma by Syngeneic Fibroblasts Genetically Engineered to Secrete the JE/MCP-1 Cytokine
1995
Histone deacetylase inhibitors in clinical development
2004
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells
2005 StandoutNobel
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
2010 StandoutNobel
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma
1998
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Chest Roentgenographic Abnormalities in IL-2 Recipients
1992
Comparison of Serum Interleukin-10 (IL-10) Levels Between Normal Volunteers and Patients with Advanced Melanoma
2001
Advances in Malignant Mesothelioma
2005 Standout
Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
1994
Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.
1990
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium
1996 StandoutNobel
Interleukin-2 Based Home Therapy of Metastatic Renal Cell Carcinoma: Risks and Benefits in 215 Consecutive Single Institution Patients
1996
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
1991 StandoutScience
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Expansion of natural killer cells but not T cells in human interleukin 2/interleukin 2 receptor (Tac) transgenic mice.
1989 StandoutNobel
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
Cytokines in Metastatic Renal Cell Carcinoma: Is It Useful to Switch to Interleukin-2 or Interferon After Failure of a First Treatment?
1999
Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2
2001
Activation and differentiation requirements of primary T cells in vitro.
1993 StandoutNobel
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA
1993
Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy
2006
A Critical Appraisal of the Quality of Quality-of-Life Measurements
1994 Standout
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
1999 Standout
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
1990
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
2016
The pharmaceutics and delivery of therapeutic polypeptides and proteins
1993
Biochemical evidence for a third chain of the interleukin-2 receptor.
1991 StandoutNobel
Cytokine Signaling Through Nonreceptor Protein Tyrosine Kinases
1995 StandoutScience
Immunobiologic Aspects of Head and Neck Cancer: Clinical and Laboratory Correlates
1991
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Use of a cDNA microarray to analyse gene expression patterns in human cancer
1996 Standout
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
1999 Standout
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
1994 StandoutScience
From the RNA world to the clinic
2016 Science
Interleukin-2: Inception, Impact, and Implications
1988 StandoutScience
Works of Douglas Orr being referenced
Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation – a clinical and histological examination
2006
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.
1991
Summary of bi-shRNA<sup>furin</sup>/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver
2014
Phase I Study of Oral CI-994 in Combination with Gemcitabine in Treatment of Patients with Advanced Cancer
2003
Clinical Pharmacology of Oral and Iv N-Methylformamide: A Pharmacologic Basis for Lack of Clinical Antineoplastic Activity
1988
Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.
1999 Nobel
Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
1987